Page last updated: 2024-12-08

imidazole-4-carboxamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

imidazole-4-carboxamide: see also related record for imidazolecarboxamide, unspecified position [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID152917
CHEMBL ID4558068
SCHEMBL ID343264
SCHEMBL ID9484700
MeSH IDM0101584

Synonyms (25)

Synonym
BB 0261092
1h-imidazole-4-carboxamide
imidazole-4-carboxamide
26832-08-6
1h-imidazole-5-carboxamide
AKOS006377405
A5267
EN300-72288
FT-0682339
S10625
AKOS015854512
SCHEMBL343264
SCHEMBL9484700
1h-imidazole-5-carboxamide #
4-imidazolecarboxamide
TS-01545
DTXSID20181325
mfcd04113065
J-016567
imidazol-5-carboxamide
AMY24018
CHEMBL4558068
CS-0149966
I1101
Z1147451838

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The current phase I study investigates the effects of sorafenib on the pharmacokinetic (PK) profile of dacarbazine and its metabolite 5-amino-imidazole-4-carboxamide (AIC)."( Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors.
Armand, JP; Brendel, E; Lathia, C; Ludwig, M; Robert, C; Ropert, S; Soria, JC, 2011
)
0.57

Compound-Compound Interactions

ExcerptReferenceRelevance
"Sorafenib, a multikinase inhibitor of Raf and several growth factor receptors, is under investigation in combination with dacarbazine, a commonly used chemotherapeutic agent for the treatment of many cancers."( Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors.
Armand, JP; Brendel, E; Lathia, C; Ludwig, M; Robert, C; Ropert, S; Soria, JC, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (29.17)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's10 (41.67)24.3611
2020's7 (29.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.88 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index5.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.85%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (96.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]